NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00171392
Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 162
- Registration Number
- NCT00171379
Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplant
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 39
- Registration Number
- NCT00171717
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 61
- Registration Number
- NCT00171509
A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 369
- Registration Number
- NCT00171093
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 212
- Registration Number
- NCT00171015
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1422
- Registration Number
- NCT00171366
- Locations
- 🇺🇸
Novartis Pharmaceuticals, E. Hanover, New Jersey, United States
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00171496
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 120
- Registration Number
- NCT00171262
- Locations
- 🇪🇸
Novartis, Madrid, Spain
6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-05-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 135
- Registration Number
- NCT00170872
© Copyright 2024. All Rights Reserved by MedPath